date:Nov 06, 2013
Royal DSM, the Life Sciences and Materials Sciences company, today reported a third quarter EBITDA of 342 million compared to 270 million in Q3 2012. This improvement of 27% was realized despite an ongoing challenging macro-economic environment.
The company said on Tuesday it was still exploring ways to reduce its exposure to the low-margin market for caprolactam, the raw material for a type of nylon with a wide range of uses from food packaging and fish nets to carpets and car parts.
The cap